- Global Pharma News & Resources

Ascletis' Ganovo Enrolled in the Basic Medical Insurance of Chengdu

Ascletis' Ganovo Enrolled in the Basic Medical Insurance of Chengdu

PR Newswire

HANGZHOU, China and SHAOXING, China, Jan. 1, 2019

HANGZHOU, China and SHAOXING, China, Jan. 1, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), a commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Ganovo® (Danoprevir) has been enrolled in the Basic Medical Insurance of Chengdu, Sichuan Province. This is another important milestone for patient access to Ganovo® after its recent enrollment in Tianjin Basic Medical Insurance Program under capped-reimbursement per patient pilot program and Shaoxing government funding subsidy program.

Ganovo® is the first direct-acting antiviral agent (DAA) developed and commercialized by a domestic company in China. Ganovo® inhibits the hepatitis C virus (HCV) NS3/4A protease that is critical to HCV replication. In the phase III clinical trial conducted in Mainland China, Ganovo regimen (Ganovo® in combination with PEGylated interferon and ribavirin) demonstrated a cure rate of 97% (SVR12) in HCV genotype 1 non-cirrhotic patients with a 12-week treatment duration. Ganovo®, in combination with Ravidasvir, an NDA accepted HCV NS5A inhibitor, and ribavirin, forms an all-oral, interferon-free HCV therapy (RDV/DNV Regimen), which offers a cure rate of 99% (SVR12) in the phase II/III clinical trial of HCV genotype 1 non-cirrhotic patients with 12-week treatment duration. In the same phase II/III clinical trial, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12) for patients with baseline NS5A resistance mutations.

Jinzi J. Wu, Ph.D., Ascletis' Founder, Chairman and CEO commented, "I'm very glad that Ganovo® has gained yet another endorsement from the medical insurance authorities and is well-recognized in the clinical community for its efficacy and safety. We anticipate Ganovo® will gain additional reimbursement access and further benefit hepatitis C patients in China."

View original content:

SOURCE Ascletis Pharma Inc.

Editor Details

Last Updated: 02-Jan-2019